Dupilumab, a dual inhibitor of IL-4 and IL-13 cytokine signaling, is indicated for the treatment of moderate-to-severe atopic dermatitis, which leads to the control of atopic dermatitis. The cytokines IL-4 and IL-13 are related to vascular inflammation, which is mediated by vascular ...
Dupilumab is the first biologic agent approved for treatment of moderate to severe atopic dermatitis (AD). Phase 3 clinical trials have shown the efficacy and safety in AD children. However, real-world evidence is still scarce. Thirty-nine pediatric patients with uncontrolled AD who regularly recei...
Dupilumab also wasapproved in the United Statesin March this year for use in adults with moderate to severe atopic dermatitis (a form of eczema) that is poorly controlled with prescription topical treatments or those who cannot use topical treatments. The EMA's decision follows results from studie...
Infection rates low among children treated with long-term dupilumab for atopic dermatitis Infection rates were lower following longer dupilumab treatment exposure in children with moderate to severe atopic dermatitis, according to a study. News
600 mg initial, then 300 mg every 2 weeks for patients with orally corticosteroid-dependent asthma or comorbid moderate-to-severeatopicdermatitis (for which dupilumab is indicated) Children under 12 years: Safety and efficacy not established
Previously, we have reported short term effectiveness and safety of dupilumab in Korea. In this study, we are trying to report the long-term effectiveness and safety of dupilumab in Korea. Ninety-nine patients with moderate to severe AD were analyzed. Th
if they're controlled. Patients with moderate atopic dermatitis average between 8 to 10 significant flares a year. Patients with severe atopic dermatitis, between 11 to 15 significant flares in a year. That's one a month or more. When we put them on these systemic medications and get them ...
Dupilumab for atopic dermatitis. PMID: 29545264 Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). PMID: 37230366 ...
参考文献:[1]. Hamilton JD, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300. 发布于 2024-03-28 13:11・IP 属地上海 ...
学术范收录的Journal Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.,目前已有全文资源,进入学术范阅读全文,查看参考文献与引证文献,参与文献内容讨论。学术范是一个在线学术交流社区,收录论文、作者、研究机构等信息,是一个与小木虫、知